Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Archives of Internal Medicine

Volumn 170, Issue 20, 2010, Pages 1842-1849

  Flynn, Anneliese ^a,b   Moscucci, Mauro ^c   Share, David ^a   Smith, Dean ^a   LaLonde, Thomas ^d   Changezi, Hameem ^e   Riba, Arthur ^f   Gurm, Hitinder S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^e GENESYS REGIONAL MEDICAL CENTER   (United States)

^f OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BALLOON DILATATION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STANDARDIZED MORTALITY RATIO; STROKE; SURVIVAL; TIME; TRANSFUSION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREND STUDY; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CORONARY CARE UNITS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 78149418369     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.381     Document Type: Article

References (31)

1. Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with STelevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(9):e82-e292.
2. Antman EM, Hand M, Armstrong PW, et al; 2004 Writing Committee Members. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296-329.
3. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283(22):2941-2947.
4. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999;100(1):14-20.
5. McNamara RL, Wang Y, Herrin J, et al; NRMI Investigators. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2006;47(11):2180-2186. (Pubitemid 43810139)
6. Gibson CM, Pride YB, Frederick PD, et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008;156(6):1035-1044.
7. Kline-Rogers E, Share D, Bondie D, et al; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002;15(5):387-392.
8. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation. 2001;104(3):263-268. (Pubitemid 32666945)
9. Moscucci M, Eagle KA, Share D, et al. Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Cardiol. 2005;45(11):1759-1765.
10. Moscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation. 2006;113(6):814-822. (Pubitemid 43754302)
11. Moscucci M, O'Connor GT, Ellis SG, et al. Validation of risk adjustment models for in-hospital percutaneous transluminal coronary angioplasty mortality on an independent data set. J Am Coll Cardiol. 1999;34(3):692-697. (Pubitemid 29436173)
12. Lilienfeld DE, Stolley PD, Lilienfeld AM. Foundations of Epidemiology. 3rd ed. New York, NY: Oxford University Press; 1994.
13. Curtin LR, Klein RJ, eds. Direct Standardization (Age-Adjusted Death Rates): Statistical Notes. Hyattsville, MD: National Center for Health Statistics; 1995.
14. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med. 1985;312(14):932-936.
15. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002.
16. Machin D. Sample Size Tables for Clinical Studies. 2nd ed. Malden, MA: Blackwell Publishers; 1997.
17. Nissen SE, Brush JE Jr, Krumholz HM. President's page: GAP-D2B: an alliance for quality. J Am Coll Cardiol. 2006;48(9):1911-1912.
18. De Luca G, Suryapranata H, Zijlstra F, et al; ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42(6):991-997.
19. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293(8):979-986.
20. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56(5):786-794.
21. Fox KA, Steg PG, Eagle KA, et al; GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA. 2007;297(17):1892-1900.
22. Wang TY, Fonarow GC, Hernandez AF, et al. The dissociation between door-toballoon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med. 2009;169(15):1411-1419.
23. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-322. (Pubitemid 124000789)
24. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy: GUSTO-1 Investigators. JAmColl Cardiol. 1996;27(7):1646-1655.
25. Goldberg RJ, Mooradd M, Gurwitz JH, et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (the Second National Registry of Myocardial Infarction). Am J Cardiol. 1998;82(3):259-264.
26. Brodie BR, Stone GW, Morice MC, et al; Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol. 2001;88(10):1085-1090.
27. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23(7):550-557.
28. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32(5):1312-1319.
29. Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J. 2003;145(4):708-715. (Pubitemid 36403502)
30. Antoniucci D, Valenti R, Moschi G, et al. Relation between preintervention angiographic evidence of coronary collateral circulation and clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol. 2002;89(2):121-125. (Pubitemid 34132896)
31. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 1989;320(10):618-627.